Nowadays, the biological equipment available for the treatment of moderate-to-severe psoriasis is plenty. Anti-interleukin-23 represents the latest class of biologic approved for the management of moderate-to-severe psoriasis. Their efficacy and safety have been assessed through two major sources: clinical trials (CTs) and real-world experiences data (RWE). Notably, the two sources differ from one another, but together, they complement information and current knowledge on both efficacy and safety of biological therapy. We carry out a review on CTs and RWE reports on the latest group of biological approved for moderate-to-severe psoriasis: anti-IL23 (guselkumab, risankizumab, and tildrakizumab).
Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data / Ruggiero, Angelo; Megna, Matteo; Fabbrocini, Gabriella; Ocampo-Garza, Sonia Sofia. - In: IMMUNOLOGIC RESEARCH. - ISSN 0257-277X. - (2023). [10.1007/s12026-022-09356-y]
Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data
Ruggiero, Angelo;Megna, Matteo;Fabbrocini, Gabriella;
2023
Abstract
Nowadays, the biological equipment available for the treatment of moderate-to-severe psoriasis is plenty. Anti-interleukin-23 represents the latest class of biologic approved for the management of moderate-to-severe psoriasis. Their efficacy and safety have been assessed through two major sources: clinical trials (CTs) and real-world experiences data (RWE). Notably, the two sources differ from one another, but together, they complement information and current knowledge on both efficacy and safety of biological therapy. We carry out a review on CTs and RWE reports on the latest group of biological approved for moderate-to-severe psoriasis: anti-IL23 (guselkumab, risankizumab, and tildrakizumab).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
